HCLTech Partners With Denodo And AWS For Clinical Trials And Diagnosis Solution
HCL Technologies Ltd. has launched an advanced clinical trials and diagnosis solution in collaboration with Denodo, a data management and Amazon Web Services ecosystem solutions provider, to accelerate the pace of diagnosis and treatment research.
Leveraging the Denodo platform, which is a data integration, management and delivery solution on AWS Cloud, HCLTech has developed data assets that can be integrated into customers' data analytics landscape for modernised reporting and analysis, the company said.
The clinical trials and diagnosis solution can help pharmaceutical companies capture insights from clinical studies, streamlining clinical trials and helping better decision-making. The solution enables healthcare providers to efficiently compare new treatments against standard ones, considering varied dosages and demographic impacts through a centralised data model that is secure with real-time access to data.
"This solution harnesses the power of logical data management to offer a single, consolidated view of detailed clinical study data that is easily accessible to patients and healthcare professionals,” said Ananth Subramanya, executive vice president, digital business services, HCLTech. “This solution significantly enhances healthcare data analytics and modernises data management to navigate trial complexities, diverse data sources and stringent regulations effectively.”
"We're thrilled to partner with HCLTech and AWS to deliver a scalable data management solution for contemporary healthcare research,” added Suresh Chandrasekaran, executive vice president, Denodo. “Denodo's unique logical approach integrates disparate data sources to create semantic data products on drugs, patients, providers and more and deliver them as on-demand data services to HCLTech applications, thereby reducing time to value and cost and improving governance."
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
